Presented at the World Immunotherapy Congress USA 2019
SYDNEY, AUSTRALIA – 6 March 2019 - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”). The data will be presented at the World Immunotherapy Congress 2019 in San Diego USA, by Dr. Fre´de´ric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer at 3:00 PM Pacific Standard Time on 5th March 2019.
For further information please download PDF attached:
Download this document